AU2014358671B2 - Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer - Google Patents

Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer Download PDF

Info

Publication number
AU2014358671B2
AU2014358671B2 AU2014358671A AU2014358671A AU2014358671B2 AU 2014358671 B2 AU2014358671 B2 AU 2014358671B2 AU 2014358671 A AU2014358671 A AU 2014358671A AU 2014358671 A AU2014358671 A AU 2014358671A AU 2014358671 B2 AU2014358671 B2 AU 2014358671B2
Authority
AU
Australia
Prior art keywords
cancer
peptide
seq
amino acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014358671A
Other languages
English (en)
Other versions
AU2014358671A1 (en
Inventor
Yoram Devary
Uziel Sandler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune System Key Ltd
Original Assignee
Immune System Key Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune System Key Ltd filed Critical Immune System Key Ltd
Publication of AU2014358671A1 publication Critical patent/AU2014358671A1/en
Application granted granted Critical
Publication of AU2014358671B2 publication Critical patent/AU2014358671B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2014358671A 2013-12-05 2014-12-04 Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer Active AU2014358671B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912156P 2013-12-05 2013-12-05
US61/912,156 2013-12-05
PCT/IL2014/051058 WO2015083167A1 (en) 2013-12-05 2014-12-04 Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer

Publications (2)

Publication Number Publication Date
AU2014358671A1 AU2014358671A1 (en) 2016-06-02
AU2014358671B2 true AU2014358671B2 (en) 2019-09-12

Family

ID=52292983

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014358671A Active AU2014358671B2 (en) 2013-12-05 2014-12-04 Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer

Country Status (11)

Country Link
US (1) US9878015B2 (enExample)
EP (1) EP3076988B1 (enExample)
JP (1) JP6609556B2 (enExample)
KR (1) KR102384795B1 (enExample)
CN (1) CN105939724B (enExample)
AU (1) AU2014358671B2 (enExample)
CA (1) CA2931023C (enExample)
DK (1) DK3076988T3 (enExample)
ES (1) ES2742856T3 (enExample)
IL (1) IL245998B (enExample)
WO (1) WO2015083167A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018130764A (ru) * 2016-02-04 2020-03-04 Имьюн Систем Ки Лтд. Стресс эндоплазматического ретикулума как прогностический инструмент в терапии рака и комбинированная терапия для лечения рака
KR20250009999A (ko) * 2022-05-27 2025-01-20 주식회사 진큐어 신규 펩타이드 및 그의 용도
WO2024228200A1 (en) * 2023-05-03 2024-11-07 Immune System Key Ltd. Cyclic d-peptides, derivatives, compositions and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046239A2 (en) * 2004-10-25 2006-05-04 Immune System Key Ltd A thymus-specific protein
WO2007091240A2 (en) * 2006-02-06 2007-08-16 Immune System Key Ltd. Treatment of immunological diseases
WO2007122622A1 (en) * 2006-04-24 2007-11-01 Immune System Key Ltd. Method of treatment of a disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100204097A1 (en) 2006-12-18 2010-08-12 Immune System Key Ltd. Therapeutic methods using a thymus peptide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046239A2 (en) * 2004-10-25 2006-05-04 Immune System Key Ltd A thymus-specific protein
WO2007091240A2 (en) * 2006-02-06 2007-08-16 Immune System Key Ltd. Treatment of immunological diseases
WO2007122622A1 (en) * 2006-04-24 2007-11-01 Immune System Key Ltd. Method of treatment of a disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SANDLER UZIEL ET AL, "NEROFE--a novel human hormone-peptide with anti-cancer activity.", JOURNAL OF EXPERIMENTAL THERAPEUTICS & ONCOLOGY 2010, (2010), vol. 8, no. 4, ISSN 1359-4117, pages 327 - 339 *
UZIEL SANDLER, ORLY DEVARY, ORI BRAITBARD, JOEL OHANA,GIDEON KASS AND YORAM DEVARY, "A Novel Human Hormone-peptide NEROFE with Stronganti Cancer Activity", RECENT ADVANCES IN CLINICAL MEDICINE, (2010), ISSN 1790-5125, ISBN 978-960-474-165-6 *

Also Published As

Publication number Publication date
CA2931023A1 (en) 2015-06-11
IL245998A0 (en) 2016-07-31
US9878015B2 (en) 2018-01-30
EP3076988A1 (en) 2016-10-12
DK3076988T3 (da) 2019-09-16
KR102384795B1 (ko) 2022-04-08
CN105939724B (zh) 2020-01-14
AU2014358671A1 (en) 2016-06-02
CN105939724A (zh) 2016-09-14
EP3076988B1 (en) 2019-06-05
IL245998B (en) 2019-12-31
KR20160085361A (ko) 2016-07-15
JP6609556B2 (ja) 2019-11-20
WO2015083167A1 (en) 2015-06-11
JP2017505755A (ja) 2017-02-23
US20160303200A1 (en) 2016-10-20
CA2931023C (en) 2023-12-19
ES2742856T3 (es) 2020-02-17

Similar Documents

Publication Publication Date Title
JP6748155B2 (ja) 線維症抑制活性を有するペプチド及びこれを含む組成物
UA123392C2 (uk) Пептид, здатний зв'язуватися з молекулою головного комплексу гістосумісності (mhc) людини i класу, та його застосування для лікування раку
US20240108686A1 (en) DPEP-1 Binding Compositions and Methods of Use
JP6104872B2 (ja) 細胞取込を最適化するための抗分泌性因子（ａｆ）の使用
US12378301B2 (en) B1SP fusion protein therapeutics, methods, and uses
AU2014358671B2 (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
US9789213B2 (en) EGFL7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis
HK1229242A1 (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
HK1229242B (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
US20250134975A1 (en) Cancer vaccine comprising epitope of c-met and use thereof
WO2025068426A1 (en) Treatment of cancers associated with beta-catenin
JP2016501856A (ja) 乳癌を処置するためのｃｄ４４ｖ６由来ペプチド

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)